Navigation Links
Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
Date:6/27/2011

LA JOLLA, Calif., June 27, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR® for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

"I am very encouraged that our approach of restoring a critical enzyme that is depleted in advanced heart failure may lead to new treatment options for those patients that continue to decline despite the best standard drug and device therapies," said Mariell Jessup, M.D., Professor of Medicine at the University of Pennsylvania's School of Medicine, who was the principal investigator and lead author of the study.  "The clinical deterioration seen in the placebo patients receiving ongoing optimal standard therapy emphasizes the tremendous unmet medical need in people with advanced heart failure. Based on these results we are encouraged that MYDICAR may one day fill this need."  

The previously announced top line results of 39 patients met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR versus placebo.  Additionally, 12 months after receiving a single infusion of MYDICAR, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003) of major cardiovascular events such as:

  • Death
  • Need for left ventricular assist device (LVAD) or cardiac transplant
  • Episodes of worsening of heart failure
  • Number of heart failure-related hospitalizations

The mean duration of hospitalization in the MYDICAR high dose group during the 12-month period was 0.4 days per patient compared with 4.5 days per patient in the placebo group. This finding is especially noteworthy because heart failure i
'/>"/>

SOURCE Celladon Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
2. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
3. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
4. Fox Chase Cancer Center Signs Agreement with Life Technologies Corporation
5. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
6. China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results
7. Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A.
8. Designed by Kids, Built by Volunteers: Roche, New Jersey Community Development Corporation, and KaBOOM! Build New Playground in Just One Day for Paterson Public School Children
9. Geminus Corporation Named Recipient of Second Annual Netsmart Technologies Customer Innovation Award
10. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
11. DURECT Corporation Announces First Quarter 2011 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 29, 2014 Global polyvinyl ... the world economic crisis during 2008-2009, especially in North ... recovered and currently is keeping to a growing trend. ... volume is utilized in the construction segment. In 2013, ... pipes, profiles, tubing, sheets and rigid film. Moreover, the ...
(Date:10/30/2014)... James Sherley says he has been working towards ASCTC ... his days as a principal investigator at the Fox Chase ... Sherley founded the ASCTC as a new Boston biotech start-up ... developed in Sherley’s research over the years since FCCC, first ... and more recently as a senior scientist at the now ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/27/2014)... North Carolina (PRWEB) October 27, 2014 ... invited earlier this month to sit down with Bryan Hamilton, ... from RPG Solutions to discuss talent in the Research Triangle ... topics that were highlighted at the roundtable include ... the Triangle, the significance of work/life balance and the unique ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... Family of, Tissue Dissection Tools, Which Have Been Used ... ... Calif., Oct. 28 PEAK Surgical, Inc., a,medical device company ... proprietary technology, has introduced two extensions to its,PEAK PlasmaBlade(TM) family ...
... Senomyx,s Discovery of a Promising New Flavor Ingredient Achieves ... Collaboration ... (Nasdaq: SNMX ), a leading company focused on using proprietary,technologies ... ingredient supply industries, announced today that it has,received a payment from ...
... to Advance P-552, DURHAM, N.C., Oct. 28 ... they have entered into an agreement to,co-develop Parion,s proprietary ... mouth associated with primary Sjogren,s syndrome., Under the ... P-552. Kainos will provide funding to help advance the,program ...
Cached Biology Technology:PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery 2PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery 3SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment 2Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment 3
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
(Date:10/29/2014)... potential of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen ... these into a human-readable text developed in manuscript within ... used to study the species distributions of ten Nearctic ... BOLD is originally designed to support the generation and ...
(Date:10/29/2014)... 2014 – Ghrelin is a hormone released by the ... is commonly viewed as a psychoactive substance that primarily ... caloric food. , This knowledge, combined with findings ... ghrelin has the potential to stimulate alcohol craving. , ... humans and found that, as they had anticipated, alcohol ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... found a critical piece in the evolutionary puzzle that ... ago. The team, from the School of Biomedical ... into more complex cells and found this crucial step ... thought. Team leader and ARC Federation Fellow ...
... The Translational Genomics Research Institute (TGen) today announced the ... the Van Andel Research Institute (VARI) that will maximize ... TGen expects the agreement to create a robust basic-science-to-translational ... for patient benefit. "We are ...
... are especially reactive to stress are more vulnerable to ... their peers. But a new longitudinal study suggests that ... well when they,re raised in supportive environments. The ... the University of California, San Francisco, and the University ...
Cached Biology News:An answer to another of life's big questions 2TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3High sensitivity to stress isn't always bad for children 2
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: